New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:20 EDTCNATConatus Pharmaceuticals price target lowered to $14 from $16 at Stifel
Stifel cut its price target on Conatus as the firm thinks the extension of P2b ACLF data timelines due to slower than expected enrollment is negative. However, the firm keeps a Buy rating on the stock.
News For CNAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
09:19 EDTCNATOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
07:32 EDTCNATConatus wins FDA fast track designation for Emricasan development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use